Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
July 16, 2025 | Creative and Design, Digital Communications, Equitable access, Health policy and government affairs, Market Access, Medical Communications, Patient support and adherence, Press Releases Branding, Sales, cell and gene therapy, clinical research, medical education, pharmacy, regulatory affairs
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position as a strategic sourcing partner across international healthcare markets. The new name reflects the evolving role of the business as a strategic global partner to manufacturers and healthcare providers worldwide in sourcing and delivering essential medicines.
The rebrand is a key step in Uniphar’s broader strategy to integrate its global operations, boost internal collaboration, and offer a seamless, high-value experience for customers, partners, and suppliers.
As the first step in this transition, BModesto Group – headquartered in the Netherlands – will adopt the Uniphar brand at the group level and operate as Uniphar | Global Sourcing in the market. Brands including BModesto, BMclinical, BMmedical, Doncaster Pharma, SynCo Pharma, Uniphar Clinical, Durbin UK, Durbin PTSI US, Pharmasource, Ostomysource and Orspec Pharma will retain their local names while benefiting from the scale and synergies of the global platform.
“The rebrand to Uniphar | Global Sourcing marks a significant milestone in our commitment to building an integrated and agile global sourcing business,” said Dermot Ryan, COO, Uniphar. “BModesto Group’s transition is the first of several steps in strengthening our identity, simplifying market engagement, and enhancing our sourcing and supply value propositions worldwide.”
“This strategic repositioning unites teams across the business,” Ryan continued, “enabling faster response times, smarter solutions, stronger global partnerships, and ultimately, better access to medicines for patients worldwide.”
With the integration of Global Sourcing, Uniphar offers a truly end-to-end pharmaceutical services platform, supporting clients across the full product lifecycle, from early access and clinical supply to commercial distribution and global market expansion.
Uniphar | Global Sourcing complements the company’s Pharma services capabilities and broadens its reach through new, strategically located facilities in the US and Europe, positioning the business to better serve clients and partners in both developed and emerging markets.
This strengthened infrastructure enables Uniphar to deliver medicines and medical products to over 180 countries, supported by a global workforce of more than 3,500 employees. The integration of these capabilities creates a unique and scalable offering that meets the evolving needs of pharmaceutical manufacturers and healthcare providers worldwide.
For more information about Global Sourcing, visit www.uniphar.com/globalsourcing.
ENDS
Media Relations:
Heather Hopkin at TALA: heather.hopkin@teamtala.com | +44 (0)7545536147
Beth O’Shea at TALA: beth.oshea@teamtala.com | +44 (0)7891481003
About Uniphar
Uniphar is a global healthcare services provider delivering innovative solutions across the product lifecycle for pharmaceutical and medtech partners. With market-leading expertise spanning global pharma services, including clinical development, regulatory, market access, medical affairs, patient support and supply chain, through to commercial and clinical, medtech, supply chain & retail, and now a unified global sourcing offering.
Uniphar connects manufacturers with healthcare providers and patients across a global footprint, supporting access to medicines in more than 180 countries and operating with a team of over 3,500 people across Europe, North America, and other key global markets. Its unique platform is designed to provide end-to-end solutions, driving better outcomes for partners, providers, and ultimately, patients around the world.
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. - Mike Ebhardt is appointed President of Uniphar Pharma...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
Uniphar Secures 10th Cell and Gene Therapy Project
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s...
Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global...
- 1
- 2